LPAR1 and Hepatic fibrosis: In line with this discovery, LPAR1 antagonism significantly reduces liver fibrosis in a murine NASH model induced by choline-deficient high-fat diet (CDHFD) in vivo, and suppresses human HSC contractility and activation in vitro [8], highlighting a potential strategy to target-activated HSCs.